DOCSLIB.ORG

产品编号 产品描述 包装规格 价格 （人民币，元） EPA0040000 Acebutolol Hydrochloride 50Mg 1200 EPA0070000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

价格 产品编号 产品描述 包装规格 （人民币，元） EPA0040000 Acebutolol hydrochloride 50mg 1200 EPA0070000 Acesulfame potassium 50mg 1200 Acesulfame potassium impurity B 5-chloro-6-methyl-1,2,3-oxathiazin- EPA0070020 15mg 1200 4(3H)-one 2,2-dioxide EPA0100000 Acetazolamide 100mg 1200 EPA0150000 Acetylcysteine 50mg 1200 EPA0152000 Acetylcysteine impurity C N,N'-diacetyl-L-cystine 10mg 1200 EPA0153000 Acetylcysteine impurity D N,S-diacetyl-L-cysteine 10mg 1200 EPA0200000 Acetylsalicylic acid 15mg 1200 EPA0202000 N-Acetyltyrosine 200mg 1200 EPA0208000 N-Acetyltryptophan 125mg 1200 EPA0220000 Aciclovir 75mg 1200 EPA0225000 Acitretin 100mg 1200 EPA0230000 Adenine 50mg 1200 EPA0230200 Adenosine 50mg 1200 EPA0300000 Adrenaline tartrate 100mg 1200 EPA0325000 Alanine (L-alpha-Form) 60mg 1200 EPA0325100 Albendazole 50mg 1200 EPA0325200 Alcuronium chloride 50mg 1200 EPA0325450 Alfacalcidol 5mg 4500 EPA0325451 Alfacalcidol - Reference Spectrum unit 1200 EPA0325500 Alfentanil hydrochloride - Reference Spectrum unit 1200 EPA0325800 Alfuzosin hydrochloride 10mg 1200 EPA0349000 Allantoin 60mg 1200 EPA0350000 Allopurinol 100mg 1200 EPA0350010 Allopurinol impurity A 5-amino-1H-pyrazole-4-carboxamide 10mg 1200 EPA0350020 Allopurinol impurity B 5-formylamino-1H-pyrazole-4-carboxamide 10mg 1200 EPA0350020 Allopurinol impurity B 5-formylamino-1H-pyrazole-4-carboxamide 10mg 1200 Allopurinol impurity C 5-(4H-1,2,4-triazol-4-yl)1H-pyrazole-4- EPA0350030 10mg 1200 Allopurinolcarboxamide impurity C 5-(4H-1,2,4-triazol-4-yl)1H-pyrazole-4- EPA0350030 10mg 1200 carboxamide EPA0350040 Allopurinol impurity D ethyl 5-amino-1H-pyrazole-4-carboxylate 15mg 1200 Allopurinol impurity E ethyl 5-(formylamino)-1H-pyrazole-4- EPA0350050 20mg 1200 carboxylate EPA0351000 Allylstrychnine bromide 10mg 1200 EPA0357000 Alprazolam 100mg 1200 EPA0360000 Alprenolol hydrochloride 100mg 1200 EPA0363000 Amantadine hydrochloride 100mg 1200 EPA0363700 Ambroxol hydrochloride 125mg 1200 EPA0365000 Amidotrizoic acid dihydrate 100mg 1200 EPA0365900 Amikacin sulfate 200mg 1200 EPA0368000 Amikacin 200mg 1200 EPA0370000 Amiloride hydrochloride 100mg 1200 EPA0420000 Aminocaproic acid 50mg 1200 EPA0460000 7-Aminodesacetoxycephalosporanic acid 20mg 1200 EPA0496000 Aminoglutethimide 125mg 1200 Aminoglutethimide impurity A (3RS)-3-(3-aminophenyl)-3- EPA0496005 20mg 1200 ethylpiperidine-2,6-dione;(3-aminoglutethimide) Aminoglutethimide impurity D 3,3'-[diazenediyldi(4,1- EPA0496020 10mg 1200 phenylene)]bis(3-ethylpiperidine-2,6-dione) (azoglutethimide) Iotalamic acid impurity A 5-Amino-2,4,6-tri-iodo-N- EPA0560000 20mg 1200 methylisophthalamic acid EPA0575000 Amiodarone hydrochloride 100mg 1200 EPA0590000 Amisulpride 10mg 1200 EPA0650000 Amobarbital 500mg 1200 EPA0700000 Amobarbital sodium 500mg 1200 EPA0800000 Amoxicillin trihydrate 200mg 1200 EPA0900000 Amfetamine sulfate - Reference Spectrum unit 1200 EPA1000000 Ampicillin (anhydrous) 220mg 1200 EPA1100000 Ampicillin trihydrate 150mg 1200 EPA1200000 Anhydrotetracycline hydrochloride 15mg 1200 EPA1202000 Citric acid (anhydrous) 50mg 1200 EPA1202800 Ethanol (anhydrous) - Reference Spectrum unit 1200 EPA1206000 Lactose (anhydrous) 100mg 1200 EPA1210000 Antazoline hydrochloride 50mg 1200 EPA1220000 Alpha-apo-oxytetracycline 20mg 1200 EPA1225000 Alfadex (Alphacyclodextrin) 150mg 1200 EPA1230000 Beta-apo-oxytetracycline 20mg 1200 EPA1250000 Aprotinin solution BRP 0.5ml 1200 EPA1269000 L-Arabinitol 10mg 1200 EPA1270000 Arginine 50mg 1200 EPA1271000 Arginine hydrochloride 50mg 1200 EPA1300000 Ascorbic acid (Vitamin C ) 100mg 1200 EPA1320000 Aspartame 40mg 1200 Aspartame impurity A 2-(5-benzyl-3,6-dioxopiperazin-2-yl)acetic acid EPA1321000 10mg 1200 (diketopiperazine) EPA1330000 Aspartic acid 50mg 1200 EPA1340000 Atenolol 100mg 1200 EPA1400000 Atropine sulfate 20mg 1200 EPA1500000 Azathioprine 100mg 1200 EPB0070000 Bacampicillin hydrochloride 120mg 1200 EPB0100000 Bacitracin zinc 62.9 IU per mg 150mg 1200 EPB0200000 Baclofen 50mg 1200 EPB0200050 Baclofen impurity A (4RS)-4-(4-chlorophenyl)pyrrolidin-2-one 50mg 1200 EPB0250000 Bambuterol hydrochloride 100mg 1200 EPB0300000 Barbital 500mg 1200 EPB0305000 Beclometasone dipropionate anhydrous 150mg 1200 EPB0400000 Bendroflumethiazide 100mg 1200 EPB0470000 Benperidol 100mg 1200 EPB0477000 Benserazide hydrochloride 50mg 1200 EPB0477010 Benserazide impurity A (RS)-2-amino-3-hydroxypropanohydrazide 20mg 1200 EPB0490000 Benzarone 10mg 1200 EPB0500000 Benzathine benzylpenicillin 200mg 1200 EPB0550000 Benzethonium chloride 100mg 1200 EPB0600000 Benzocaine 50mg 1200 EPB0650000 Hydrous benzoyl peroxide - Reference Spectrum unit 1200 EPB0670000 Benzyl benzoate - Reference Spectrum unit 1200 EPB0680000 S-Benzylmercaptoacetyltriglycin 10mg 1200 EPB0700000 Benzylpenicillin potassium 100mg 1200 EPB0900000 Benzylpenicillin sodium 200mg 1200 EPB0950000 Betadex (Betacyclodextrin) 200mg 1200 EPB0990000 Betahistine mesilate 100mg 1200 EPB1000000 Betamethasone 75mg 1200 EPB1030000 Betamethasone acetate 100mg 1200 EPB1040000 Betamethasone diproprionate 150mg 1200 EPB1045000 Betamethasone sodium phosphate 100mg 1200 EPB1054000 Betamethasone-17-valerate 100mg 1200 EPB1055000 Betamethasone-21-valerate 15mg 1200 EPB1103000 Betaxolol hydrochloride 60mg 1200 Betaxolol impurity A (2RS)-1-(4-ethylphenoxy)-3-[(1- EPB1103100 10mg 1200 methylethyl)amino]propan-2-ol EPB1110000 Bifonazole 100mg 1200 Bifonazole impurity B 4-[(RS)-(biphenyl-4-yl)phenylmethyl]-1H- EPB1110004 10mg 1200 imidazole trifluoroacetate EPB1115000 Bezafibrate 100mg 1200 EPB1116000 Biotin (Vitamin H) 20mg 1200 EPB1120000 Biperiden hydrochloride 60mg 1200 Biperiden impurity A (1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en- EPB1121000 20mg 1200 2-yl]-1-phenyl-3-(piperidin-1-yl)propan-1-ol (endo form) EPB1140000 Bisacodyl 50mg 1200 EPB1141000 Bleomycin sulfate 7mg 1200 EPB1142000 Bordetella pertussis mouse antiserum BRP 0.5mg 1350 EPB1143000 Bromazepam 60mg 1200 EPB1145000 Bromhexine hydrochloride 100mg 1200 EPB1150000 Bromocriptine mesilate 30mg 1200 EPB1152000 Bromperidol 100mg 1200 EPB1152050 Bromperidol decanoate 60mg 1200 EPB1153000 Brompheniramine maleate 100mg 1200 EPB1155000 Brucella melitensis Rev. 1 strain BRP 1ml 4185 EPB1156000 Bufexamac 100mg 1200 EPB1157300 Budesonide 110mg 1200 EPB1157400 Buflomedil hydrochloride 100mg 1200 Buflomedil impurity B 4-(pyrrolidin-1-yl)-1-(4-hydroxy-2,6- EPB1157410 20mg 1200 dimethoxyphenyl)butan-1-one EPB1158000 Bumetanide 150mg 1200 EPB1160000 Bupivacaine hydrochloride 100mg 1200 EPB1168000 Buserelin 2mg 1200 EPB1168020 D-His-Buserelin vial 1200 EPB1170000 Busulfan 50mg 1200 EPB1212000 Butylhydroxyanisole 60mg 1200 EPB1215000 Butylhydroxytoluene Plastic additive 07 50mg 1200 EPB1217000 Butyl parahydroxybenzoate 100mg 1200 Ibuprofen impurity B (2RS)-2-(4-Butylphenyl)propionic acid (0,06% EPB1220000 1.1ml 1200 solution in Acetonitrile) EPC0100000 Caffeine 70mg 1200 EPC0166000 Calcifediol 5mg 2250 EPC0166001 Calcifediol - Reference Spectrum unit 1200 N-acetyl-cys1-calcitonin (for about 0.1mg N-acetyl-cys-1-calcitonin EPC0200010 20mg 1200 in mannitol per vial) EPC0225000 Calcitriol 10mg 15000 EPC0226000 Calcitriol - Reference Spectrum unit 1200 EPC0249000 Calcium ascorbate - Reference Spectrum unit 1200 EPC0250000 Calcium folinate 100mg 1200 EPC0299000 Calcium glucoheptonate 60mg 1200 EPC0300000 Calcium gluconate 100mg 1200 EPC0340000 Calcium levulinate dihydrate 250mg 1200 EPC0350000 Calcium oxalate monohydrate 500mg 1200 EPC0400000 Calcium pantothenate 60mg 1200 EPC0405000 Camphor (racemic) 50mg 1200 EPC0410000 Canrenone 50mg 1200 EPC0426000 Caprylic acid 200mg 1200 EPC0430000 Captopril 10mg 1200 EPC0450000 Carbamazepine 200mg 1200 EPC0451000 Carbasalate calcium - Reference Spectrum unit 1200 EPC0455000 Carbenicillin sodium 50mg 1200 EPC0460000 Carbidopa 50mg 1200 EPC0465000 Carbimazole 120mg 1200 EPC0470000 Carbocisteine 60mg 1200 EPC0499900 Carbon dioxide - Reference Spectrum unit 1200 EPC0550000 Carboplatin - Reference Spectrum unit 1200 EPC0580004 Carmustine - Reference Spectrum unit 1200 EPC0580010 Carmustine impurity A 1,3-bis(2-chloroethyl)urea 20mg 1200 EPC0600000 Casein BRP 100g 1965 EPC0630000 Cefaclor 450mg 1200 EPC0640000 Delta-3-Cefaclor 20mg 1200 EPC0650000 Cefadroxil 250mg 1200 EPC0675000 Cefalexin monohydrate 150mg 1200 EPC0682000 Cefalotin sodium 100mg 1200 EPC0682300 Cefamandole nafate 125mg 1200 EPC0682400 Cefatrizine propylene glycol 150mg 1200 Cefatrizine impurity A 7-amino-(6R,7R)-3-[(2H-1,2,3-triazol-4- EPC0682410 yl)sulfanyl]-methyl-8-oxo-5-thia-1-azabicyclo[4.2.O]oct-2-ene-2- 60mg 1200 carboxylic acid(7-ACA triazole) EPC0682800 Cefazolin 150mg 1200 EPC0684000 Cefixime 200mg 1200 EPC0684750 Cefoperazone dihydrate 100mg 1200 EPC0684800 Cefoperazone sodium - Reference Spectrum unit 1200 EPC0685000 Cefotaxime sodium 30mg 1200 EPC0688000 Cefoxitin sodium 100mg 1200 EPC0690000 Cefradine 300mg 1200 EPC0690500 Ceftazidime 200mg 1200 EPC0691000 Ceftriaxone sodium 100mg 1200 EPC0692000 Ceftriaxone impurity A (E-isomer) 10mg 1200 EPC0694990 Cefuroxime axetil 60mg 1200 EPC0695000 Cefuroxime sodium 150mg 1200 EPC0698005 Cellulose acetate butyrate - Reference Spectrum unit 1200 EPC0700000 Cephaeline hydrochloride 15mg 1200 EPC0980650 Cetirizine dihydrochloride 100mg 1200 Cetirizine impurity A (RS)-1-[(4- EPC0980651 10mg 1200 chlorophenyl)phenylmethyl]piperazine EPC0984100 Cetostearyl isononanoate - Reference Spectrum unit 1200 EPC0990000 Cetyl alcohol 300mg 1200 EPC1000000 Cetylpyridinium chloride 20mg 1200 EPC1050000 Chenodeoxycholic acid 125mg 1200 EPC1100000 Chlorambucil 100mg 1200 EPC1200000 Chloramphenicol 500mg 1200 EPC1300000
Recommended publications
  • THIORIDAZINE Thioridazinum

    THIORIDAZINE Thioridazinum

    EUROPEAN PHARMACOPOEIA 5.8 Thioridazine Detection: spectrophotometer at 240 nm. C. R = CO-C2H5 : testosterone propionate, Injection: 20 µl of the test solution and reference β D. R = CO-CH(CH3)2 : 3-oxoandrost-4-en-17 -yl solutions (a) and (b). 2-methylpropanoate (testosterone isobutyrate), Run time: twice the retention time of testosterone β isocaproate. E. R = CO-[CH2]4-CH3 : 3-oxoandrost-4-en-17 -yl hexanoate (testosterone caproate), Identification of impurities: use the chromatogram supplied with testosterone isocaproate for system suitability CRS F. R = CO-[CH2]5-CH3 : testosterone enantate, and the chromatogram obtained with reference solution (a) toidentifythepeaksduetoimpuritiesA,B,C,D,E,FandG. Relative retention with reference to testosterone isocaproate (retention time = about 14 min): impurity A = about 0.2; impurity B = about 0.4; impurity C = about 0.5; impurity D = about 0.7; impurity G = about 0.8; impurity E = about 1.1; impurity F = about 1.4. System suitability: reference solution (a): G. 3-oxoandrost-4-en-17α-yl 4-methylpentanoate — peak-to-valley ratio: minimum 2.5, where Hp =height abovethebaselineofthepeakduetoimpurityEand (epitestosterone isocaproate). Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to testosterone isocaproate. 07/2007:2005 Limits: — impurities A, B, C, D, E, F, G:foreachimpurity,notmore THIORIDAZINE than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); Thioridazinum — unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent); — total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent); — disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) C H N S M 370.6 (0.05 per cent).
  • A Comparison of Fluticasone Propionate, 1 Mg Daily, with Beclomethasone Dipropionate, 2 Mg Daily, in the Treatment of Severe Asthma

    A Comparison of Fluticasone Propionate, 1 Mg Daily, with Beclomethasone Dipropionate, 2 Mg Daily, in the Treatment of Severe Asthma

    Copyright ©ERS Joumals Ltd 1993 Eur Respir J , 1993, 6, Sn-884 European Respiratory Joumal Printed in UK - all rights reserved ISSN 0903 - 1936 A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma N.C. Bames*, G. Marone**, G.U. Di Maria***, S. Visser, I. Utama++, S.L. Payne+++, on behalf of an International Study Group A comparison of fluticasone propionate. 1 mg daily, with beclomethasone dipropionate, • The London Chest Hospital, London, 2 mg daily, in the treatment of severe asthma. N. C. Bames, G. Marone, G.U. Di Maria, UK. ** Servizio di Allergologia e S. Visser. l Utama, S.L Payne, on behalf of an International Study Group. @ERS Immunologia Clinica. I Clinica Medica Journals Ltd 1993. Universita, Napoli, Italy. *** lnstituto Malattie Respiratorie, Ospedale Tomaselli, ABSTRACT: We wanted w compare the efficacy and safety of fluticasone propi­ Catania, Sicily, Italy. onate, a new topically active inhaled corticosteroid, to that of high dose beclo­ + H.F. Verwoerd Hospital, Pretoria, South methasone dipropionate, in severe adult asthma. Africa. ++ St Laurentius Ziekenhius, 1 Patients currently receiving between 1.5-2.0 mg·day- of an inhaled corticoster­ CV Roermond, The Netherlands. +++ oid were treated for six weeks in a double-blind, randomized, parallel group study Glaxo Group Research Ltd, Greenford, with 1 mg·day-1 fluticasone propionate (n•82), or 2 mg·day·1 beclometbasone Middlesex, UK. dipropionate (n•72). Mean morning peak expirarory flow rates (PEFR) increased from 303 w 321 Correspondence: N.C. Bames l·min-1 with fluticasone propionate, and from 294 w 319 l·min·1 with beclometbasone The London Chest Hospital dipropionate.
  • Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye

    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye

    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Thesis Submitted to the Faculty of Science in Fulfilment of the Requirements for the Degree of Doctor in Science (Chemistry) Sander Delahaye Promotor Prof. Dr. Frédéric Lynen Leden van de lees- en examencommissie: Voorzitter: Prof. Dr. J. Martins Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent Leescommissie: Prof. Dr. K. Broeckhoven Vakgroep Chemische Ingenieurstechnieken en Industriële Scheikunde (CHIS), Faculteit Ingenieurswetenschappen, Vrije Universiteit Brussel Prof. Dr. D. Cabooter Laboratorium Farmaceutische Analyse, Faculteit Farmaceutische Wetenschappen, KU Leuven Dr. L. Balcaen Vakgroep Analytische Chemie, Faculteit Wetenschappen, UGent Examencommissie: Dr. I. Francois UPC²/SFC & Strategic Separation Technologies Business Development Manager Europe and India (Waters) Prof. Dr. K. Van Geem Vakgroep Chemische Proceskunde en Technische Chemie Faculteit Ingenieurswetenschappen en Architectuur, UGent Prof. Dr. F. Lynen Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent This research was funded by the Agency for Innovation by Science and Technology in Flanders (IWT - Vlaanderen) Table of Contents I General Introduction and Scope 1 1. General introduction . .1 2. Scope . .5 3. References . .6 II The Emergence of Packed-Column Supercritical Fluid Chromatography as an Alternative for HPLC 9 1. Introduction . 10 2. Definition of supercritical fluids . 10 3. Physico-chemical properties of supercritical fluids . 10 4. The use of supercritical fluids as extraction solvent and as mobile phase in chromatography . 15 5. SFC over the years . 16 6. Contemporary pSFC conditions and stationary phases . 17 7. Most important applications of supercritical fluid chromatography . 20 7.1. Preparative SFC applications . 20 7.2. Analytical SFC applications . 21 8. Nomenclature issues . 21 9.
  • Flonase Sensimist Allergy Relief (Fluticasone Furoate)

    Flonase Sensimist Allergy Relief (Fluticasone Furoate)

    Flonase® Sensimist™ Allergy Relief (fluticasone furoate) – Rx-to-OTC Approval • On February 8, 2017, GlaxoSmithKline Consumer Healthcare announced the launch of Flonase Sensimist Allergy Relief (fluticasone furoate) nasal spray, as an over the counter (OTC) treatment to temporarily relieve symptoms of hay fever or other upper respiratory allergies: nasal congestion; runny nose; sneezing; itchy nose; and itchy, watery eyes (in ages 12 years and older). — Flonase Sensimist Allergy Relief contains 27.5 mcg/spray of fluticasone furoate. — Flonase Sensimist Allergy Relief should not be used in children less than 2 years of age. • Previously, fluticasone furoate was only available by prescription as Veramyst®. Veramyst is no longer commercially available. • Fluticasone is also available OTC as brand (Flonase® Allergy Relief, Children’s Flonase® Allergy Relief) and generic products containing 50 mcg/spray of fluticasone propionate. — These products share the same indications as Flonase Sensimist Allergy Relief, but are not intended for children under 4 years of age. • Prescription fluticasone propionate nasal spray (50 mcg/spray) is available generically and indicated for the management of the nasal symptoms of perennial non-allergic rhinitis in adult and pediatric patients aged 4 years and older. • Warnings for Flonase Sensimist Allergy Relief state the following: — Do not use: in children under 2 years of age, to treat asthma, if there is an injury or surgery to the nose that is not fully healed, or if an allergic reaction to Flonase Sensimist Allergy Relief or any of its ingredients has occurred. — Ask a doctor prior to use if the patient has or had glaucoma or cataracts.
  • Etats Rapides

    Etats Rapides

    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
  • Uncertainty Reigns in Error Disclosure Debate

    Uncertainty Reigns in Error Disclosure Debate

    74 Practice Trends S K I N & A L L E R G Y N E W S • August 2008 Uncertainty Reigns in Error Disclosure Debate B Y J A N E M . A N D E R S O N ington, Seattle, told attendees at the annual desire full disclosure of harmful errors, harmful to the patient,” Dr. Gallagher said. Contributing Writer meeting of the American College of Physi- while at the same time worrying that The University of Washington recently cians that physicians are unsure about what health care workers might hide them. In surveyed 4,000 physicians about commu- WA S H I N G T O N — Physicians generally to include when they disclose a medical er- disclosure, they want “an explicit state- nication with patients, colleagues, and believe that medical errors—especially ror. But he added that physicians are ac- ment that an error occurred,” details of health care institutions about errors. those that cause an adverse event—should tively debating the best way to proceed. what happened, and the implications for According to Dr. Gallagher, the survey be disclosed to patients, but there is dis- “Over the next 5 years, we’re going to see their health, he said. on error disclosure was sent to 2,000 physi- agreement about the level of detail that very exciting changes,” he said. “I think Physicians define errors more narrowly cians in Washington State and 2,000 Cana- should be provided, according to a physi- physicians as a profession will be leading than patients do. They agree in principle dian physicians.
  • Connecticut Medicaid

    Connecticut Medicaid

    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
  • FLONASE (Fluticasone Propionate) Nasal Spray Bacterial, Viral, Or Parasitic Infection; Ocular Herpes Simplex)

    FLONASE (Fluticasone Propionate) Nasal Spray Bacterial, Viral, Or Parasitic Infection; Ocular Herpes Simplex)

    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, These highlights do not include all the information needed to use contact dermatitis, rash) have been reported after administration of FLONASE safely and effectively. See full prescribing information for FLONASE nasal spray. Discontinue FLONASE nasal spray if such FLONASE. reactions occur. (5.3) • Potential worsening of infections (e.g., existing tuberculosis; fungal, FLONASE (fluticasone propionate) nasal spray bacterial, viral, or parasitic infection; ocular herpes simplex). Use with Initial U.S. Approval: 1994 caution in patients with these infections. More serious or even fatal course --------------------------- RECENT MAJOR CHANGES --------------------------- of chickenpox or measles can occur in susceptible patients. (5.4) • Hypercorticism and adrenal suppression may occur with very high Warnings and Precautions, Glaucoma and Cataracts (5.2) 1/2019 dosages or at the regular dosage in susceptible individuals. If such --------------------------- INDICATIONS AND USAGE ---------------------------- changes occur, discontinue FLONASE nasal spray slowly. (5.5) FLONASE nasal spray is a corticosteroid indicated for the management of the • Monitor growth of pediatric patients. (5.7) nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients ------------------------------ ADVERSE REACTIONS ------------------------------ aged 4 years and older. (1) The most common adverse reactions (>3%) are headache, pharyngitis, ----------------------- DOSAGE AND ADMINISTRATION ----------------------- epistaxis, nasal burning/nasal irritation, nausea/vomiting, asthma symptoms, For intranasal use only. Recommended starting dosages: and cough. (6.1) • Adults: 2 sprays per nostril once daily (200 mcg per day). (2.1) To report SUSPECTED ADVERSE REACTIONS, contact • Adolescents and children aged 4 years and older: 1 spray per nostril once GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or daily (100 mcg per day).
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug

    Utah Medicaid Pharmacy and Therapeutics Committee Drug

    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Single Ingredient Nasal Corticosteroids Beclomethasone dipropionate (Qnasl) Beclomethasone dipropionate monohydrate (Beconase AQ) Budesonide (Rhinocort) Ciclesonide (Omnaris, Zetonna) Flunisolide (Generic) Fluticasone Furoate (Flonase Sensimist) Fluticasone Propionate (Flonase, Xhance) Mometasone Furoate (Nasonex) Triamcinolone Acetonide (Nasacort) AHFS Classification: 52.08.08 Corticosteroids (EENT) Final Report February 2018 Review prepared by: Valerie Gonzales, Pharm.D., Clinical Pharmacist Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Abbreviations ................................................................................................................................................ 2 Executive Summary ....................................................................................................................................... 3 Introduction .................................................................................................................................................. 5 Table 1. Nasal corticosteroid products .............................................................................................
  • Version 10 February 2012

    Version 10 February 2012

    CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Zoreeda 25 Mikrogramm/125 Mikrogramm pro Dosis - Druckgasinhalation, Suspension Zoreeda 25 Mikrogramm/250 Mikrogramm pro Dosis - Druckgasinhalation, Suspension Fluticasone propionate, Salmeterol xinafoate Date: 11.05.2015 This module reflects the scientific discussion for the approval of Salmeterol plus Fluticason Propionat momaja 25 Mikrogramm/250 Mikrogramm Druckgasinhalator, Suspension and Salmeterol plus Fluticason-propionat momaja 25 Mikrogramm/125 Mikrogramm Druckgasinhalator, Suspension. The procedure was finalised at 04.08.2014. For information on changes after this date please refer to the module ‘Update’. 1/26 I. INTRODUCTION Based on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Zoreeda 25 Mikrogramm/125 Mikrogramm pro Dosis - Druckgasinhalation, Suspension and Zoreeda 25 Mikrogramm/250 Mikrogramm pro Dosis - Druckgasinhalation, from Cipla Europe NV. The product is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta-2-agonist. A comprehensive description of the indications and posology is given in the SmPC. The marketing authorisation has been granted pursuant to Article 10(3)of Directive 2001/83/EC. Fluticasone propionate is a glucocorticoid anti-asthmatic inhalant (anti-inflammatory). Salmeterol xinafoate is a selective beta-2-adrenoceptor agonist (bronchodilator). II. QUALITY ASPECTS II.1 Introduction Salmeterol xinafoate and fluticasone propionate pressurised inhalation suspension comprises an aluminium canister with a suitable metering valve and a plastic actuator with dose indicator and fitted with dustcap in pouch with a silica gel bag.
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019

    Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019

    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, BP July 2019 Mikromol Follow LGC on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from pharmacopoeias, correct at the time of production. We retained all spelling and information as provided by the pharmacopoeias. The list was compiled with caution, however, errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeial data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at lgcstandards.com/mikromol. Stay connected via LinkedIn (LGC Mikromol) or Twitter @LGCMikromol. Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel: +44 (0)20 8943 8480 Fax: +44 (0)20 8943 7554 E-mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1
  • TITLE: Fluticasone Furoate Versus Fluticasone Propionate for Seasonal Allergic Rhinitis: a Review of the Clinical and Cost-Effectiveness

    TITLE: Fluticasone Furoate Versus Fluticasone Propionate for Seasonal Allergic Rhinitis: a Review of the Clinical and Cost-Effectiveness

    TITLE: Fluticasone Furoate versus Fluticasone Propionate for Seasonal Allergic Rhinitis: A Review of the Clinical and Cost-Effectiveness DATE: 13 June 2011 CONTEXT AND POLICY ISSUES: Seasonal allergic rhinitis is a common disorder with an US prevalence of about 10-30% in adults and 40% in children, affecting close to 60 million people.1,2 The Canadian Allergy, Asthma and Immunology Foundation estimates that 20-25% of Canadians have allergic rhinitis.3 In addition to allergen avoidance and immunotherapy, antihistamines and corticosteroids nasal spray are used to control nasal and ocular symptoms.4,5 Fluticasone furoate nasal spray (Avamys™ by GlaxoSmythKline Inc.) was approved by Health Canada in August 2007 for the treatment of seasonal allergic rhinitis.6 The efficacy of fluticasone furoate nasal spray for the treatment of nasal and ocular symptoms of allergic rhinitis was shown in a recent systematic review,7 as well as in randomized, double-blind, placebo- controlled studies.8,9 Fluticasone furoate nasal spray was not associated with hypothalamic- pituitary-adrenal axis suppression as shown in a randomized, double blind, placebo- and active- controlled (prednisone) study.10 To help in the consideration of formulary coverage of fluticasone furoate (Avamys™) for seasonal allergic rhinitis, this report compares the clinical and cost-effectiveness of fluticasone furoate with fluticasone propionate for the treatment of seasonal allergic rhinitis. RESEARCH QUESTIONS: 1) What is the clinical effectiveness of fluticasone furoate for seasonal allergic rhinitis as compared to fluticasone propionate? 2) What is the cost-effectiveness of fluticasone furoate for seasonal allergic rhinitis as compared to fluticasone propionate? Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada.